USPTO serial 97425881
KNACKGEN
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- —
- Examiner
- DONINGER, CHRISTOPHER G
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 686 means your mark is published in the USPTO Official Gazette and in the 30-day opposition period. If no opposition is filed, prosecution typically continues toward registration or a Notice of Allowance. Monitor the opposition window. After it closes, watch for Notice of Allowance (intent-to-use) or registration (use-based).
Need help with KNACKGEN?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Tomas M. Casalins
Tomas M. Casalins FOX HORAN & CAMERINI LLP885 THIRD AVENUE, 17TH FLOORNEW YORK, NY 10022United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical preparations for the treatment and prevention of psychological disorders; Pharmaceutical preparations for the treatment and prevention of epilepsy disorders; Pharmaceutical preparations for the treatment and prevention of diabetes and diabetic neuropathy; Pharmaceutical preparations for the treatment and prevention of irritable bowel syndrome; Pharmaceutical preparations for the treatment and prevention of neurodegenerative diseases and disorders; Pharmaceutical preparations for the treatment and prevention of osteoporosis; Pharmaceutical preparations for the treatment and prevention of pain and neuropathic pain; Pharmaceutical preparations for the treatment and prevention of peripheral nervous system diseases and disorders; Pharmaceutical preparations for the treatment and prevention of digestive tract, gastrointestinal and dermatological diseases and disorders; Pharmaceutical preparations for the treatment and prevention of respiratory system diseases and disorders; Pharmaceutical preparations for the treatment and prevention of skin diseases, allergies and rheumatic disorders; Pharmaceutical preparations for the treatment and prevention of sexual dysfunction; Pharmaceutical preparations for the treatment and prevention of symptoms associated with uterine fibroids; Pharmaceutical preparations for the treatment and prevention of Alzheimer's disease; Pharmaceutical preparations for the treatment and prevention of urinary incontinence and overactive bladder; Pharmaceutical preparations for the treatment and prevention of ophthalmic related disorders and diseases; Pharmaceutical preparations for the treatment and prevention of musculoskeletal related diseases and disorders; Pharmaceutical preparations for the treatment and prevention of hormone disorders and deficiencies; Pharmaceutical preparations for the treatment and prevention of cardiovascular and blood pressure disorders; Pharmaceutical preparations for the treatment and prevention of metabolic, endocrine and kidney related diseases and disorders; Pharmaceutical preparations for the treatment and prevention of nausea and vomiting; Pharmaceutical preparations for the treatment and prevention of AIDS-related disorders and diseases; Pharmaceutical preparations for the treatment and prevention of viral and bacterial infections; Pharmaceutical preparations for the treatment and prevention of depression; Pharmaceutical preparations for the treatment of exposure to toxic agents; Pharmaceutical preparations for the treatment of cancer; Pharmaceutical preparations for the support and promotion of bone strength and health; Pharmaceutical preparations for use as injectable anesthetics; Pharmaceutical preparations for use as contraceptives; Pharmaceutical preparations for fertility enhancement purposes; Pharmaceutical preparations for use in hormone replacement therapy; Pharmaceutical preparations for inducing labor and facilitating nursing; Pharmaceutical preparations, namely, injectable contraceptives | ACTIVE | — |
| 035 | Advertising planning; Advertising services, public relations and marketing services, namely, promoting and marketing the goods and services of others through all public communication means; Business management; Business operation, business administration and office functions | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Oct 27, 2026 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Oct 27, 2026 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Oct 21, 2026 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Sep 25, 2026 | ERRR | ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED | — |
| Jul 24, 2026 | ERRR | ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED | — |
| Jul 21, 2026 | OTHE | CASE RETURNED TO EXAMINATION | — |
| Jul 21, 2026 | IUCN | NOTICE OF ALLOWANCE CANCELLED | — |
| Jul 21, 2026 | DOCK | ASSIGNED TO EXAMINER | — |
| Jul 21, 2026 | PCBG | PETITION TO DIRECTOR - CHANGE BASIS - GRANTED | — |
| Jul 13, 2026 | ERTI | TEAS RESPONSE TO PETITION INQUIRY LETTER | — |
| Jul 7, 2026 | PILM | PETITION INQUIRY LETTER ISSUED | — |
| Jul 6, 2026 | APET | ASSIGNED TO PETITION STAFF | — |
| May 20, 2026 | CORV | REVIEW OF CORRESPONDENCE COMPLETE | — |
| May 19, 2026 | EPPA | TEAS POST PUBLICATION AMENDMENT RECEIVED | — |
| May 18, 2026 | TPAD | TEAS PETITION TO AMEND BASIS RECEIVED | — |
| May 9, 2026 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| May 8, 2026 | EX5G | SOU EXTENSION 5 GRANTED | — |
| May 8, 2026 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| Dec 10, 2025 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Dec 9, 2025 | EXT5 | SOU EXTENSION 5 FILED | — |
| Jun 21, 2025 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Jun 20, 2025 | EX4G | SOU EXTENSION 4 GRANTED | — |
| Jun 20, 2025 | EXT4 | SOU EXTENSION 4 FILED | — |
| Jun 20, 2025 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Dec 14, 2024 | EX3G | SOU EXTENSION 3 GRANTED | — |
| Dec 14, 2024 | EXT3 | SOU EXTENSION 3 FILED | — |
| Dec 13, 2024 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Dec 13, 2024 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Jun 18, 2024 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Jun 18, 2024 | EX2G | SOU EXTENSION 2 GRANTED | — |
| Jun 18, 2024 | EXT2 | SOU EXTENSION 2 FILED | — |
| Jun 18, 2024 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| May 1, 2024 | DOCK | ASSIGNED TO EXAMINER | — |
| Dec 21, 2023 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Dec 19, 2023 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Dec 19, 2023 | EXT1 | SOU EXTENSION 1 FILED | — |
| Dec 19, 2023 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Nov 13, 2023 | DOCK | ASSIGNED TO EXAMINER | — |
| Jun 20, 2023 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Apr 25, 2023 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Apr 25, 2023 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Apr 5, 2023 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Mar 17, 2023 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Mar 16, 2023 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Mar 16, 2023 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Mar 16, 2023 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Mar 16, 2023 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Mar 12, 2023 | DOCK | ASSIGNED TO EXAMINER | — |
| May 31, 2022 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| May 27, 2022 | NWAP | NEW APPLICATION ENTERED | — |